Business
Perimeter Medical Imaging AI to Present at Upcoming Virtual Investor Conferences
TORONTO, ON / ACCESSWIRE / November 11, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"Perimeter Medical Imaging AI to Present at Upcoming Virtual Investor ConferencesTORONTO, ON / ACCESSWIRE / November 11, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC) (\"Perimeter\" or the \"Company\"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, announced today that Jeremy Sobotta, Perimeter's Chief Executive Officer, will present a corporate overview at the following virtual conferences:Texas Life Science Forum, Medical Devices Plenary Session, on Thursday, November 12, 2020 at 11:00 am ET (10:00 am CST). Registration link can be found here: https://whova.com/portal/registration/vtlsf_202011/Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 11:30 am ET. The presentation will be broadcast live and archived on the Company's website at: https://ir.perimetermed.com/The above-listed dates and times are subject to change. Details on company presentations and webcasts can be found on the \"Investors\" section of Perimeter's website at: https://ir.perimetermed.com/About Perimeter Medical Imaging AI, Inc. Perimeter Medical Imaging AI (TSXV:PINK)(FSE:4PC) is a Toronto-based company with U.S. headquarters in Dallas, Texas that is developing, with plans to commercialize, advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. Perimeter's OTIS™ platform is a point-of-care imaging system that provides clinicians with real-time, ultra-high-resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during a clinical procedure in addition to standard of care tissue assessment for decision making during the procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter's OTIS™ platform is cleared by FDA as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. In addition, Perimeter is developing advance...